Document:

EX-10.2

 Exhibit 10.2 
 FORM OF VOTING AGREEMENT 
 THIS VOTING AGREEMENT (this
“Agreement”) is made and entered into as of November 19, 2012 by and between Wright Medical Group, Inc., a Delaware corporation (“Parent”), and the undersigned Stockholder (the “Stockholder”)
of BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”). 
 WITNESSETH: 

WHEREAS, Parent, Achilles Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger
Sub”), Achilles Acquisition Subsidiary, LLC, a Delaware limited liability company and a direct wholly owned Subsidiary of Parent, and the Company have entered into an Agreement and Plan of Merger of even date herewith (as it may be amended
from time to time, the “Merger Agreement”), which provides for, among other things, the merger of Merger Sub with and into the Company (the “Merger”) with the Company continuing as the surviving corporation of the
Merger and pursuant to which all outstanding shares of capital stock of the Company will be converted into the right to receive the consideration set forth in the Merger Agreement (the “Merger Consideration”). 

WHEREAS, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)) of that number of shares of Company Common Stock (as defined in the Merger Agreement), and, if applicable, the holder of one or more Company Options (as defined in the Merger Agreement) to purchase that number of
shares of Company Common Stock, in each case, as set forth on the signature page of this Agreement. 
 WHEREAS, as a condition
and inducement to the willingness of Parent and Merger Sub to enter into the Merger Agreement, the Stockholder (in the Stockholder’s capacity as such) has agreed to enter into this Agreement. 

NOW, THEREFORE, intending to be legally bound, the parties hereto agree as follows: 

1. Certain Definitions. All capitalized terms that are used but not defined herein shall have the respective meanings ascribed to
them in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following respective meanings: 
 (a) “Expiration Date” shall mean the earliest to occur of (i) such date and time as the Merger Agreement shall have been validly terminated pursuant to Article IX thereof,
(ii) such date and time as the Merger shall become effective in accordance with the terms and provisions of the Merger Agreement, (iii) such date and time as the Merger Agreement shall have been amended, without the Stockholder’s
consent, to adversely affect the Merger Consideration payable to the Stockholder, or (iv) September 30, 2013. 
 (b)
“Person” shall mean any individual, corporation, limited liability company, general or limited partnership, trust, unincorporated association or other entity of any kind or nature, or any governmental authority. 

(c) “Shares” shall mean (i) all equity securities of the Company (including all shares of Company Common Stock and
all Company Options and other rights to acquire shares of Company Common Stock) owned by the Stockholder as of the date hereof, and (ii) all additional equity securities of the Company (including all additional shares of Company Common Stock
and all additional Company Options and other rights to acquire shares of Company Common Stock) of which the Stockholder acquires ownership during the period from the date of this Agreement through the Expiration Date (including by way of stock
dividend or distribution, split-up, recapitalization, combination, exchange of shares and the like). 

 (d) “Transfer” A Person shall be deemed to have effected a
“Transfer” of a Share if such Person directly or indirectly (i) sells, pledges, encumbers, assigns, grants an option with respect to, transfers, tenders or disposes of such Share or any interest in such Share, or
(ii) enters into an agreement or commitment providing for the sale of, pledge of, encumbrance of, assignment of, grant of an option with respect to, transfer, tender of or disposition of such Share or any interest therein. 

2. Transfer of Shares. 
 (a) Transfer Restrictions. During the term of this Agreement, the Stockholder shall not Transfer (or cause or permit the Transfer of) any of the Shares, or enter into any agreement relating
thereto, except (i) by selling already-owned Shares either to pay the exercise price upon the exercise of a Company Option or to satisfy the Stockholder’s tax withholding obligation upon the exercise of a Company Option, in each case as
permitted by any Company Compensation and Benefit Plan, (ii) transferring Shares to Affiliates, limited partners, members, immediate family members, a trust established for the benefit of the Stockholder and/or for the benefit of one or more
members of the Stockholder’s immediate family or charitable organizations or upon the death of the Stockholder, provided that, as a condition to such Transfer, the recipient agrees to be bound by this Agreement and delivers a Proxy (as
defined below) in the form attached hereto as Exhibit A, or (iii) with Parent’s prior written consent and in Parent’s sole discretion. Any Transfer, or purported Transfer, of Shares in breach or violation of this Agreement
shall be void and of no force or effect. 
 (b) Transfer of Voting Rights. During the term of this Agreement, the
Stockholder shall not deposit (or cause or permit the deposit of) any Shares in a voting trust or grant any proxy or enter into any voting agreement or similar agreement in contravention of the obligations of the Stockholder under this Agreement
with respect to any of the Shares. 
 3. Agreement to Vote Shares. 

(a) During the term of this Agreement, at every meeting of the stockholders of the Company, and at every adjournment or postponement
thereof, and on every action or approval by written consent of the stockholders of Company, the Stockholder (in the Stockholder’s capacity as such), to the extent not voted by the Person(s) appointed under the Proxy, shall, or shall cause the
holder of record on any applicable record date to, vote all Shares that are then-owned by such Stockholder and entitled to vote or act by written consent: 
 (i) in favor of the adoption of the Merger Agreement and in favor of the Merger and any other transactions contemplated by the Merger Agreement; 

(ii) against approval of any proposal made in opposition to, in competition with, or would result in a breach of, the Merger Agreement
or the Merger or any other transactions contemplated by the Merger Agreement; and 
 (iii) against any of the following actions
(other than those actions that relate to the Merger and any other transactions contemplated by the Merger Agreement): (A) any merger, consolidation, business combination, reorganization or recapitalization of or involving the Company or any of
its Subsidiaries, (B) any sale, lease or transfer of all or substantially all of the assets of the Company or any of its Subsidiaries, (C) any reorganization, recapitalization, dissolution, liquidation or winding up of the Company or any
of its Subsidiaries, (D) any material change in the capitalization of the 

  
 - 2 -

 
Company or any of its Subsidiaries, or the corporate structure of the Company or any of its Subsidiaries, (E) any Acquisition Proposal with respect to the Company or any of its Subsidiaries,
or (F) any other action that would reasonably be expected to materially impede, interfere with, delay, postpone, adversely affect the Merger or any other transactions contemplated by the Merger Agreement. 

The Stockholder shall retain at all times the right to vote its Shares in its sole discretion and without any other limitation on any matters other than
those set forth in clauses (i), (ii) and (iii) that are at any time or from time to time presented for consideration to the Company’s stockholders generally. 
 (b) In the event that a meeting of the stockholders of the Company is held, the Stockholder shall, or shall cause the holder of record of the Shares on any applicable record date to, appear at such
meeting or otherwise cause the Shares to be counted as present thereat for purposes of establishing a quorum. 
 (c) The
Stockholder shall not enter into any agreement or understanding with any Person to vote or give instructions in any manner inconsistent with the terms of this Section 3. 

4. Agreement Not to Exercise Appraisal Rights. The Stockholder shall not exercise, and hereby irrevocably and unconditionally
waives, any statutory rights (including under Section 262 of the DGCL) to demand appraisal of any Shares that may arise in connection with the Merger. Notwithstanding the foregoing, nothing in this Section 4 shall constitute, or be
deemed to constitute, a waiver or release by the Stockholder of any claim or cause of action against Parent or Merger Sub to the extent arising out of a breach of this Agreement or the Merger Agreement by Parent. 

5. Directors and Officers. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall limit
or restrict the Stockholder (or a designee of the Stockholder) who is a director or officer of the Company from acting in such capacity or fulfilling the obligations of such office, including by voting, in his capacity as a director or officer of
the Company, in the Stockholder’s (or its designee’s) sole discretion on any matter (it being understood that this Agreement shall apply to the Stockholder solely in the Stockholder’s capacity as a Stockholder of the Company),
including with respect to Section 7.2 of the Merger Agreement. In this regard, the Stockholder shall not be deemed to make any agreement or understanding in this Agreement in the Stockholder’s capacity as a director or officer of the
Company, including with respect to Section 7.2 of the Merger Agreement. 
 6. Irrevocable Proxy. Concurrently with
the execution of this Agreement, the Stockholder shall deliver to Parent a proxy in the form attached hereto as Exhibit A (the “Proxy”), which shall be irrevocable to the fullest extent permissible by law, with respect to the
Shares. 
 7. Representations and Warranties of the Stockholder. The Stockholder hereby represents and warrants to Parent
as follows: 
 (a) Power; Binding Agreement. The Stockholder has full power and authority to execute and deliver
this Agreement and the Proxy, to perform the Stockholder’s obligations hereunder and under the Proxy and to consummate the transactions contemplated hereby. This Agreement and the Proxy has been duly executed and delivered by the Stockholder,
and, assuming this Agreement constitutes a valid and binding obligation of Parent, constitutes a valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with its terms, except that such enforceability may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws affecting or relating to creditors’ rights generally and is subject to general principles of equity (regardless of whether such enforceability is
considered in a proceeding in equity or law). 

  
 - 3 -

 (b) No Conflicts. None of the execution and delivery by the Stockholder of
this Agreement or the Proxy, the performance by the Stockholder of its obligations hereunder or under the Proxy or the consummation by the Stockholder of the transactions contemplated hereby will (i) result in a violation or breach of any
agreement to which the Stockholder is a party or by which the Stockholder may be bound, including any voting agreement or voting trust, except for violations, breaches or defaults that would not in any material respect impair or adversely effect the
ability of the Stockholder to perform its obligations under this Agreement, or (ii) violate any order, writ, injunction, decree, judgment, order, statute, rule, or regulation applicable to the Stockholder. 

(c) Ownership of Shares. The Stockholder (i) is the sole beneficial owner of the shares of Company Common Stock set
forth on the signature page of this Agreement, all of which are free and clear of any liens, adverse claims, charges, security interests, pledges or options, proxies, voting trusts or agreements, understandings or agreements, or any other rights or
encumbrances whatsoever (“Encumbrances”), (ii) is the sole holder of the Company Options that are exercisable for the number of shares of Company Common Stock set forth on the signature page of this Agreement, all of which
Company Options and shares of Company Common Stock issuable upon the exercise or vesting of such Company Options are, or in the case of Company Common Stock received upon exercise or vesting of such Company Options after the date hereof will be,
free and clear of any Encumbrances, and (iii) except as set forth on the signature page to this Agreement, does not own, beneficially or otherwise, any securities of the Company other than the shares of Company Common Stock or Company Options,
and shares of Company Common Stock issuable upon the exercise or vesting of such Company Options, set forth on the signature page of this Agreement. 
 (d) Voting Power. The Stockholder has or will have sole voting power, sole power of disposition, sole power to issue instructions with respect to the matters set forth herein and sole power
to agree to all of the matters set forth in this Agreement, in each case with respect to all of the Shares, with no limitations, qualifications or restrictions on such rights, subject to applicable federal securities laws and the terms of this
Agreement. 
 (e) No Finder’s Fees. No broker, investment banker, financial advisor, finder, agent or other Person
is entitled to any broker’s, finder’s, financial adviser’s or other similar fee or commission in connection with this Agreement based upon arrangements made by or on behalf of the Stockholder in his, her or its capacity as such.

 (f) No Legal Actions. The Stockholder agrees that the Stockholder will not in the Stockholder’s capacity as a
stockholder of the Company bring, commence, institute, maintain, prosecute or voluntarily aid any action, claim, suit or cause of action, in law or in equity, in any court or before any governmental entity, which (i) challenges the validity of
or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder, either alone or together with the other Company voting agreements and proxies to be
delivered in connection with the execution of the Merger Agreement, or the approval of the Merger Agreement by the board of directors of the Company, breaches any fiduciary duty of the board of directors of the Company or any member thereof.

 8. Certain Restrictions. The Stockholder shall not, directly or indirectly, take any voluntary action that would make
any representation or warranty of the Stockholder contained herein untrue or incorrect in any material respect. 
 9.
Disclosure. The Stockholder shall permit Parent to publish and disclose in all documents and schedules filed with the SEC, and, after providing the Stockholder with a reasonable opportunity to review and comment upon, any press release or
other disclosure document that Parent reasonably 

  
 - 4 -

 
determines to be necessary or desirable in connection with the Merger and any transactions related to the Merger, the Stockholder’s identity and ownership of Shares and the nature of the
Stockholder’s commitments, arrangements and understandings under this Agreement. 
 10. No Ownership Interest.
Nothing contained in this Agreement shall be deemed to vest in Parent any direct or indirect ownership or incidence of ownership of or with respect to any Shares. Except as provided in this Agreement, all rights, ownership and economic benefits
relating to the Shares shall remain vested in and belong to the Stockholder. 
 11. Further Assurances. Subject to the
terms and conditions of this Agreement, upon request of Parent, the Stockholder shall use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to fulfill such
Stockholder’s obligations under this Agreement. 
 12. Stop Transfer Instructions. At all times commencing with the
execution and delivery of this Agreement and continuing until the Expiration Date, in furtherance of this Agreement, the Stockholder hereby authorizes the Company or its counsel to notify the Company’s transfer agent that there is a stop
transfer order with respect to all of the Shares of the Stockholder (and that this Agreement places limits on the voting and transfer of such Shares),subject to the provisions hereof and provided that any such stop transfer order and notice
will immediately be withdrawn and terminated by Company following the Expiration Date. 
 13. Termination. This Agreement
and the Proxy, and all rights and obligations of the parties hereunder and thereunder, shall terminate and shall have no further force or effect as of the Expiration Date. Notwithstanding the foregoing, nothing set forth in this
Section 13 or elsewhere in this Agreement shall relieve either party hereto from liability, or otherwise limit the liability of either party hereto, for any intentional breach of this Agreement prior to such termination; provided
that in no event shall the Stockholder’s monetary damages exceed the aggregate Merger Consideration to which they would be entitled pursuant to the Merger Agreement; provided, further, that, the foregoing proviso shall in no
event impair or otherwise impact Parent’s right to seek specific performance or injunctive relief pursuant to Section 14(d) below. This Section 13 and Sections 1, 5, and 14 (as applicable) shall
survive any termination of this Agreement. 
 14. Miscellaneous. 

(a) Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or
enforceability of the other provisions of this Agreement, which will remain in full force and effect. In the event any Governmental Entity of competent jurisdiction holds any provision of this Agreement to be null, void or unenforceable, the parties
hereto shall negotiate in good faith and execute and deliver an amendment to this Agreement in order, as nearly as possible, to effectuate, to the extent permitted by law, the original intent of the parties hereto with respect to such provision.

 (b) Binding Effect and Assignment. This Agreement and all of the provisions hereof shall be binding upon and
inure to the benefit of the parties hereto and their respective successors and permitted assigns, but neither this Agreement nor any of the rights, interests or obligations of the parties hereto may be assigned by either of the parties (whether by
operation of law or otherwise) without prior written consent of the other. 
 (c) Amendments; Waiver. This
Agreement may be amended by the parties hereto, and the terms and conditions hereof may be waived, only by an instrument in writing signed on behalf of 

  
 - 5 -

 
each of the parties hereto, or, in the case of a waiver, by an instrument signed on behalf of the party waiving compliance. Notwithstanding the foregoing, no failure or delay by any party hereto
in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or future exercise of any other right hereunder. 

(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge that Parent shall be irreparably harmed and
that there shall be no adequate remedy at law for a violation of any of the covenants or agreements of the Stockholder set forth herein. Therefore, it is agreed that, in addition to any other remedies that may be available to Parent upon any such
violation, Parent shall have the right to enforce such covenants and agreements by specific performance, injunctive relief or by any other means available to Parent at law or in equity. 

(e) Notices. Any notice, request, instruction or other communication under this Agreement shall be in writing and delivered
by hand or international courier service, by facsimile (with written confirmation of transmission) or by electronic mail, with a copy thereof delivered or sent as provided below: 

If to Parent: 

Wright Medical Group, Inc. 
 5677 Airline Road 
 Arlington, Tennessee 38002 

Attention: Chief Executive Officer 
 Facsimile: (901) 867-4320 
 Wright Medical Group, Inc. 

5677 Airline Road 

Arlington, Tennessee 38002 
 Attention: General Counsel 
 Facsimile: (901) 867-4398 

with copies (which shall not constitute notice) to: 
 Wilson Sonsini Goodrich & Rosati 
 Professional Corporation 

12235 El Camino Real 
 San Diego, California 92103-3002 
 Attention: Martin J. Waters, Esq. 

Telecopy No.: (858) 350-2399 
 and: 
 Wilson Sonsini Goodrich & Rosati 

Professional Corporation 
 One Market Street 
 Spear Tower, Suite 3300 

San Francisco, California 94105-1126 
 Attention: Robert T. Ishii, Esq. 
 Telecopy No.: (415) 947-2099 

  
 - 6 -

 If to the Stockholder: 

[Name] 

[Address] 

[Address] 

Telecopy No.: 

with a copy (which shall not constitute notice) to: 
 Ropes & Gray LLP 
 Prudential Tower 

800 Boylston Street 
 Boston, MA 02199 
 Attention: Paul Kinsella 

Telecopy No.: (617) 235-0822 
 (f) No Waiver. The failure of either party hereto to exercise any right, power or remedy provided under this Agreement or otherwise available in respect of this Agreement at law or in equity, or to
insist upon compliance by any other party with its obligation under this Agreement, and any custom or practice of the parties at variance with the terms of this Agreement, shall not constitute a waiver by such party of such party’s right to
exercise any such or other right, power or remedy or to demand such compliance. 
 (g) No Third Party
Beneficiaries. This Agreement is not intended to confer and does not confer upon any Person other than the parties hereto any rights or remedies hereunder. 
 (h) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable
principles of conflicts of law thereof. 
 (i) Consent to Jurisdiction. Each of the parties hereto
(a) irrevocably consents to the service of the summons and complaint and any other process in any action or proceeding relating to the this Agreement, the Proxy, or the agreements delivered by the Stockholder in connection herewith or the
transactions contemplated hereby or thereby, for and on behalf of itself or any of its properties or assets, in accordance with Section 14(e) or in such other manner as may be permitted by applicable Law, and nothing in this
Section 14(i) shall affect the right of any party to serve legal process in any other manner permitted by applicable Law; (b) irrevocably and unconditionally consents and submits itself and its properties and assets in any action or
proceeding to the exclusive jurisdiction of the Court of Chancery of the State of Delaware (or, only if the Court of Chancery of the State of Delaware declines to accept jurisdiction over a particular matter, any federal court within the State of
Delaware) in the event any dispute or controversy arises out of this Agreement, the Proxy, or the agreements delivered by the Stockholder in connection herewith or the transactions contemplated hereby or thereby, or for recognition and enforcement
of any judgment in respect thereof; (c) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; (d) agrees that any actions or proceedings arising in connection
with this Agreement, the Proxy or the agreements delivered by the Stockholder in connection herewith or the transactions contemplated hereby or thereby shall be brought, tried and determined only in the Court of Chancery of the State of Delaware
(or, only if the Court of Chancery of the State of Delaware declines to accept jurisdiction over a particular matter, any federal court within the State of Delaware); (e) waives any objection that it may now or hereafter have to the venue of
any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same; and (f) agrees that it will not

  
 - 7 -

 
bring any action relating to this Agreement, the Proxy or the agreements delivered by the Stockholder in connection herewith or the transactions contemplated hereby or thereby in any court other
than the aforesaid courts. Each of Parent and Stockholder agrees that a final judgment in any action or proceeding in such courts as provided above shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any
other manner provided by applicable Law. 
 (j) Rules of Construction. The parties hereto hereby waive the
application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document. 

(k) Entire Agreement. This Agreement and the Proxy contain the entire understanding of the parties hereto in respect of the
subject matter hereof, and supersede all prior negotiations, agreements and understandings, both written and oral, between the parties hereto with respect to the subject matter hereof. 

(l) Interpretation. 
 (i) Whenever the words “include,” “includes” or “including” are used in this Agreement they shall be deemed to be followed by the words “without limitation.”

 (ii) The article and section headings contained in this Agreement are solely for the purpose of reference, are not part of
the agreement of the parties hereto and shall not in any way affect or be deemed to affect the meaning or interpretation of this Agreement. 
 (m) Expenses. All fees, costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such fees, costs and
expenses. 
 (n) Counterparts. This Agreement may be executed in several counterparts, each of which shall be an
original, but all of which together shall constitute one and the same agreement. 
 (o) No Obligation to Exercise Company
Options. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall obligate the Stockholder to exercise any Company Options or other right to acquire any shares of Company Common Stock. 

[Remainder of Page Intentionally Left Blank] 

  
 - 8 -

 IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first above written. 
  

									
	PARENT	 		 		 	STOCKHOLDER
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

				
	Title:	 	  
	 		 	
				
		 		 		 	Shares beneficially owned as of the date hereof:
				
		 		 		 	                 shares of Company Common Stock
				
		 		 		 	                 shares of Company Common Stock issuable upon exercise or vesting of
Company Options

 [Signature Page to Voting Agreement] 

 EXHIBIT A 

IRREVOCABLE PROXY 
 The undersigned Stockholder (the “Stockholder”) of BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), hereby irrevocably (to the fullest extent
permitted by law) appoints Wright Medical Group, Inc., a Delaware corporation (“Parent”), acting through any of its Chief Executive Officer, Chief Financial Officer or General Counsel, as the sole and exclusive attorneys and proxies
of the undersigned to vote and exercise all voting and related rights (to the full extent that the undersigned is entitled to do so) with respect to all of the shares of capital stock of the Company that now are or hereafter may be beneficially
owned by the undersigned, and any and all other shares or equity securities of the Company issued or issuable in respect thereof on or after the date hereof (collectively, the “Shares”) in accordance with the terms of this
Irrevocable Proxy until the Expiration Date (as defined below); provided, however, that such proxy and voting and related rights are expressly limited to the matters discussed in clauses (i) through (iii) in the fourth
paragraph of this Irrevocable Proxy. Upon the undersigned’s execution of this Irrevocable Proxy, any and all prior proxies given by the undersigned with respect to any Shares are hereby revoked and the undersigned agrees not to grant any
subsequent proxies with respect to the Shares until after the Expiration Date. 
 This Irrevocable Proxy is irrevocable to the
fullest extent permitted by law, is coupled with an interest and is granted pursuant to that certain Voting Agreement of even date herewith by and between Parent and the undersigned Stockholder (the “Voting Agreement”), and is
granted as a condition and inducement to the willingness of Parent and Achilles Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”) to enter into that certain Agreement and Plan of
Merger of even date herewith (as it may be amended from time to time, the “Merger Agreement”), among Parent, Merger Sub, Achilles Acquisition Subsidiary, LLC, a Delaware limited liability company and a direct wholly owned Subsidiary
of Parent, and the Company. The Merger Agreement provides for, among other things, the merger of Merger Sub with and into the Company (the “Merger”) with the Company continuing as the surviving corporation of the Merger and pursuant
to which all outstanding shares of capital stock of the Company will be converted into the right to receive the consideration set forth in the Merger Agreement (the “Merger Consideration”). 

As used herein, the term “Expiration Date” shall mean the earliest to occur of (i) such date and time as the Merger
Agreement shall have been validly terminated pursuant to Article IX thereof, (ii) such date and time as the Merger shall become effective in accordance with the terms and provisions of the Merger Agreement, (iii) such date and time as the
Merger Agreement shall have been amended, without the Stockholder’s consent, to reduce the Merger Consideration payable to the Stockholder or (iv) December 31, 2013. 

The attorneys and proxies named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to the
Expiration Date, to act as the undersigned’s attorney and proxy to vote the Shares, and to exercise all voting, consent and similar rights of the undersigned with respect to the Shares (including, without limitation, the power to execute and
deliver written consents) at every annual, special, adjourned or postponed meeting of stockholders of the Company and in every written consent in lieu of such meeting: 
 (i) in favor of the adoption of the Merger Agreement and in favor of the Merger and any other transactions contemplated by the Merger Agreement; 

 (ii) against approval of any proposal made in opposition to, in competition with, or would
result in a breach of, the Merger Agreement or the Merger or any other transactions contemplated by the Merger Agreement; and 

(iii) against any of the following actions (other than those actions that relate to the Merger and any other transactions contemplated by
the Merger Agreement): (A) any merger, consolidation, business combination, reorganization or recapitalization of or involving the Company or any of its Subsidiaries, (B) any sale, lease or transfer of all or substantially all of the
assets of the Company or any of its Subsidiaries, (C) any reorganization, recapitalization, dissolution, liquidation or winding up of the Company or any of its Subsidiaries, (D) any material change in the capitalization of the Company or
any of its Subsidiaries, or the corporate structure of the Company or any of its Subsidiaries, (E) any Acquisition Proposal with respect to the Company or any of its Subsidiaries, or (F) any other action that would reasonably be expected
to materially impede, interfere with, delay, postpone or discourage the Merger or any other transactions contemplated by the Merger Agreement. 
 The attorneys and proxies named above may not exercise this Irrevocable Proxy on any other matter. The undersigned Stockholder may vote the Shares in its sole discretion on all other matters. 

Any obligation of the undersigned hereunder shall be binding upon the successors and permitted assigns of the undersigned. 

This Irrevocable Proxy shall terminate, and be of no further force and effect, automatically upon the Expiration Date. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the undersigned has executed and caused to be effective this Irrevocable
Proxy as of             , 2012. 
  

			
	 STOCKHOLDER

		
	By:	 	  

	Name:EX-10.3

 Exhibit 10.3 
 EMPLOYMENT AGREEMENT 
 This EMPLOYMENT AGREEMENT
(“Agreement”) made effective as of July 17, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Larry Bullock (the “Executive”). 

In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows: 

1. Employment. The Company agrees to employ the Executive and the Executive agrees to be employed by the Company as Chief
Financial Officer and to be responsible for the typical management responsibilities expected of an officer holding such position and such other responsibilities customarily pertaining to such office as may be assigned to Executive from time to time
by the Chief Executive Officer of the Company, all for the Period of Employment as provided in Section 2 below and upon the terms and conditions provided in the Agreement. 

2. Term. The period of Executive’s employment under this Agreement, will commence on July 17, 2012 , and shall continue
for a period of two (2) years through July 16, 2014, subject to extension or termination as provided in this Agreement (“Period of Employment”). Any expiration or termination of this Agreement shall not affect the term of the
Indemnification Agreement dated May 12, 2006 (“Indemnification Agreement”) and the Confidential Information and Inventions Agreement dated January 14, 2004 (“Confidential Information and Inventions Agreement”) between
the Parties. To the extent that Executive’s employment continues following the expiration and nonrenewal of this Agreement, the Executives employment shall continue at-will, however Executive’s rights with respect to Without Cause
Termination shall continue to the extent set forth in Section 8. 
 3. Duties. During the Period of Employment, the
Executive shall devote their full business time, attention and skill to the business and affairs of the Company and its Affiliates. The Executive will perform faithfully the duties that may be assigned to him from time to time in accordance herewith
by the Chief Executive Officer of the Company. 
 4. Compensation. For all services rendered by the Executive in any
capacity during the Period of Employment, the Executive shall be compensated as follows: 
 (a) Base
Salary. The Company shall pay the Executive an annual base salary of $283,600 (“Base Salary”). Base Salary shall be payable according to the customary payroll practices of the Company but in no event less frequently than twice each
month. The Base Salary shall be reviewed each fiscal period and shall be subject to increase according to the policies and practices adopted by the Company from time to time. 

(b) Incentive Compensation Award. The Executive shall also be eligible to receive annual incentive bonuses
consisting of cash and/or options to purchase Company common stock consistent with annual incentive awards for other members of the senior management team. The payment of such bonuses shall be based on the performance and satisfaction of specific
milestones mutually agreed upon by the Chief Executive Officer and 

 
the Executive, and shall be further based upon the Executive’s performance as evaluated by the Chief Executive Officer. In no event shall the payment of any annual incentive bonus to the
Executive be made later than March 15 of the calendar year next following the calendar year during which such annual incentive bonus is earned. 
 (d) Additional Benefits. The Executive will be entitled to participate in all employee benefit plans or programs and receive all benefits and perquisites for which any salaried employees are
eligible under any existing or future plan or program established by the Company or its affiliates and available to similarly situated employees of the Company, including participation in stock option plans. The Executive may participate to the
extent permissible under the terms and provisions of such plans or programs. These may include group hospitalization, health, dental care, life or other insurance, sick leave plans, travel or accident insurance and disability insurance. Nothing in
this Agreement will preclude the Company or Company affiliates from amending or terminating any of the plans or programs applicable to salaried employees or senior executives as long as the total value of all benefits is not materially decreased.
The Executive will be entitled to annual paid time off, consistent with the Company’s paid time off policy and Company holidays as determined by the Company. The Company will provide Executive with sufficient equipment, supplies and resources
to accomplish their duties and will purchase and/or reimburse Executive for the cost of maintaining preapproved professional memberships. 
 5. Business Expenses and Other Expenses. The Company will reimburse the Executive for all reasonable travel and other expenses incurred by the Executive in connection with the performance of their
duties and obligations under this Agreement. 
 6. Disability. 

(a) In the event of disability of the Executive during the Period of Employment, the Company will continue to pay the
Executive according to the compensation provisions of this Agreement during the period of the disability, until such time as any long term disability insurance benefits accruing to the Executive are available. However, in the event the Executive is
disabled for twelve (12) weeks (consecutive or nonconsecutive) during any twelve (12) month period, the Company may terminate the employment of the Executive. In this case, normal compensation will cease, except for earned but unpaid Base
Salary and, effective as of his termination date, the Executive shall be entitled to receive salary continuation for a period of six (6) months thereafter, to be paid in substantially equal installments in accordance with the Company’s
regular payroll practices applicable to similarly situated active employees and determined by reference to his Base Salary as in effect on the day immediately prior to his termination date. 

(b) During the period the Executive is receiving payments of either regular compensation or disability insurance described
in this Agreement and to the extent reasonable considering the Executive’s disability, the Executive will furnish information and assistance to the Company and from time to time will make themselves available to the Company to undertake
assignments consistent with their prior position with the Company. If the Company fails to make a payment or provide a benefit required as part of the Agreement, the Executive’s obligation to furnish information and assistance will end.

  
 2 

 (c) For purposes of this Agreement, the Executive will be considered to be
“disabled” if he satisfies the requirements necessary to receive benefits under the Company’s long-term disability plan or, in the absence of any such plan, under any insurance policy providing benefits for long-term disabilities that
is procured for the Executive pursuant to this Agreement or otherwise. 
 7. Death. In the event of the death of the
Executive during the Period of Employment, the Company’s obligation to make payments under this Agreement shall cease as of the date of death, except for earned but unpaid Base Salary. 

8. Effect of Termination of Employment. 
 (a) If the Executive’s employment terminates due to a Without Cause Termination, as defined below, the Company will provide the Executive nine (9) months’ Base Salary as in effect at
the time of the termination plus an appropriately prorated amount of the previous year’s cash bonus on the Company’s regular payroll dates for such Base Salary or cash bonus. Additionally, the benefits and perquisites described in this
Agreement as in effect at the date of termination of employment will be continued for nine (9) months to the extent permissible under the law and consistent with the tax status of such benefit plans. Amounts that the Company is obligated to pay
hereunder, including amounts paid by the Company to third parties to maintain benefit and perquisites, shall be less any amount the Executive receives from a third party for services provided as an employee, consultant, agent or the like, including
any cash or non-cash consideration such as stock or stock options. Furthermore, all outstanding stock options, restricted stock, restricted stock units, and any other unvested equity incentives shall become fully exercisable and vested as of the
Date of Termination and shall remain exercisable for their stated terms. Subject to Section 12 below, the salary continuation payments described in this Section 8 will commence within fourteen (14) days of the Company’s receipt
of the Executive’s executed general release of claims under Section 8(b) of this Agreement, and to the extent permissible under Section 12 below, such salary continuation payments shall be made retroactive back to the date the
Executive’s employment with the Company terminates. 
 (b) All severance compensation provided for herein
shall be expressly conditioned upon the Executive’s execution, delivery, and non-revocation of a general release of claims in the form set forth as Exhibit A, hereto. All severance compensation provided for herein shall be further expressly
conditioned upon the Executive complying with all post-employment obligations set forth herein and set forth in the Indemnification Agreement and the Confidential Information and Inventions Agreement. 

(c) If the Executive’s employment terminates due to Termination for Cause (as defined below), breach of this
Agreement by Executive or resignation by Executive, earned but unpaid Base Salary will be paid on a pro-rated basis for the year in which the termination occurs. No other payments will be made or benefits provided by the Company. 

  
 3 

 (d) For this Agreement, the following terms have the following meanings:

 (i) “Termination for Cause” means termination of the Executive’s employment by the
Company’s Chief Executive Officer or Board of Directors acting in good faith by the Company by written notice to the Executive specifying the event relied upon for such termination, due to the Executive’s willful misconduct with respect to
their duties under this Agreement, including but not limited to conviction for a felony or a common law fraud that results in or is likely to result in economic damage to the Company. Executive will be provided a reasonable opportunity prior to any
determination for “Cause”, to present his case before the Board of Directors of the Company with counsel. 
 (ii) “Without Cause Termination” means “constructive termination” or actual termination of the Executive’s employment other than due to death, disability, Termination for Cause,
or resignation by Executive. Constructive Termination shall occur upon Executive’s resignation as a result of either of the following trigger events: (A) a significant change to job scope or job responsibilities, (B) a relocation of
Company headquarters of more than 50 miles, or (C) the expiration of this Agreement in the absence of a renewal, extension, or superseding Agreement; provided that the Executive gives the Company notice of such Constructive Termination within
ninety (90) days of such trigger event, and the Company fails to cure such trigger event within thirty (30) days of such notice of Constructive Termination and such resignation is effective within sixty (60) days of expiration of the
Company’s thirty (30) day cure period. 
 9. Other Duties of the Executive during and after the Period of
Employment. 
 (a) The Executive will, with reasonable notice during or after the Period of Employment,
furnish information as may be in their possession and cooperate with the Company as may reasonably be requested in connection with any claims or legal actions in which the Company is or may become a party. 

(b) The Executive recognizes and acknowledges that all non-public information pertaining to the affairs, business,
clients, customers or other relationships of the Company is confidential and is a unique and valuable asset of the Company. Access to and knowledge of this information are essential to the performance of the Executive’s duties under this
Agreement. The Executive will not during the Period of Employment and for 36 months thereafter except to the extent reasonably necessary in performance of the duties under this Agreement, or as required by law, give to any person, firm, association,
corporation or governmental agency any non-public information, including but not limited to information relating to the affairs, business, clients, customers, technology or other relationships of the Company and any Confidential Information as that
term is defined in the Confident Information and Inventions Agreement. The Executive will not make use of such information for his own purposes or for the benefit of any person or organization other than the Company. All records, memoranda, etc.,
relating to the business of the Company, 

  
 4 

 
whether made by the Executive or otherwise coming into his possession, are confidential and will remain the property of the Company. Confidential information shall not include information that
(i) becomes generally available to the public other than as a result of disclosure by the Executive, (ii) was available to the Executive on a non-confidential basis prior to disclosure to the Executive in connection with his duties to the
Company, provided that the source of such information is not known to the Executive to be bound by a confidentiality agreement or other contractual obligation of confidentiality to the Company or (iii) becomes available to the Executive on a
non-confidential basis from a source other than the Company (or any agent, employee or affiliate of Company) provided such source is not known to the Executive to be bound by a confidentiality agreement or other contractual obligation of
confidentiality to the Company. 
 (c) During the Period of Employment, the Executive will not use his status
with the Company to obtain loans, goods or services from another organization on terms that would not be available to him in the absence of his relationship to the Company. During the period of his employment and for a period of 12 months
thereafter, the Executive will not directly or indirectly manage, consult or work for, serve as employee, officer, director, consultant, agent or subcontractor for, finance, or own any part of or exercise management control over any business or
entity wherein the Executive is directly or indirectly engaged in the development and/or commercialization of a Competitive Product. A “Competitive Product” shall mean any product intended for use in orthopedics, that contains recombinant
platelet-derived growth factor, recombinant insulin-like growth factor, or any recombinant osteoinductive protein, including bone morphogenetic protein or any product containing any other protein intended to be used for tissue repair or
regeneration. In addition, during such 12 month period Executive will not engage, directly or indirectly, in any business activity or enterprise which is a “Competitive Activity”. For purposes hereof, “Competitive Activity” means
the making of investments in or the provision of capital to any enterprise (or an Affiliate), or to any person in connection with any enterprise (or an Affiliate thereof), with respect in which the Company has invested or provided capital or
proposed, in writing, to invest or provide capital during the term of the Executive’s employment, or to pursue any similar investment opportunity with any individual or enterprise introduced to the Executive or Company directly in connection
with the performance of the Executive’s duties to the Company during the term of his employment, in each case in the area of tissue repair or regeneration. For purposes of this restriction, the receipt of stock, stock options or restricted
stock for any reason (including as consideration for services or otherwise) shall be deemed an investment in the issuing company or any Affiliates thereof. This restriction shall not apply to any investment opportunity that has been declined by the
Company. “Affiliate” shall mean any company, corporation, business or entity that is controlled by, controlling, or under common control with a company. The Executive acknowledges that the covenants contained herein are reasonable as to
geographic and temporal scope. For a twelve month period after termination of the Period of Employment for any reason, the Executive will not solicit to hire any employee of the Company or solicit any employee to leave the employ of the Company.

  
 5 

 (d) After the Period of Employment, upon reasonable notice the Executive
shall provide the Company with sufficient information to verify compliance with his post-employment obligations hereunder, including providing periodic reports detailing any compensation received from another party during the severance period
outlined above, and promptly responding to specific requests from the Company regarding possible violations of any restrictive covenant hereunder or under any other agreement with the Company. 

(e) The Executive acknowledges that the breach or threatened or attempted breach of any provision of Section 9 would
cause irreparable harm to the Company not compensable in monetary damages and that the Company shall be entitled, in addition to all other applicable remedies, to a temporary and permanent injunction and a decree for specific performance of the
terms of Section 9 without being required to prove damages or furnish any bond or other security. 
 (f) The
Executive shall not be bound by the provisions of Section 9 in the event of the default by the Company in its obligations under this Agreement that are to be performed upon or after termination of this Agreement, provided that such default is
not cured by the Company within sixty (60) days of the Company’s receipt from the Executive of a written notice of default. 
 (g) For purposes of Section 9, the “Company” shall include any person or entity that, directly or indirectly, controls or is controlled by the Company or is under common control with the
Company. 
 10. Indemnification; Litigation. 
 The Executive and the Company previously entered into the Indemnification Agreement under which the Company has agreed to indemnify the Executive from and against certain liability associated with his
providing services as an executive of the Company. The parties hereby reaffirm the Indemnification Agreement, which shall remain effective together with this Employment Agreement. In the event of a conflict between this Agreement and the
Indemnification Agreement, the Indemnification Agreement shall supersede this Agreement. 
 11. Effect of Change in
Control. 
 (a) In the event there is a Change in Control (as defined below) and in connection with such
event or within the twelve (12) month period following such event Executive is terminated in a Without Cause Termination, or Executive elects to resign upon written notice to the Company following an event that constitutes Good Reason (as
defined below), all outstanding stock options, restricted stock, restricted stock units, and any other unvested equity incentives shall become fully exercisable and vested as of the effective date of such termination or resignation and shall remain
exercisable for their full stated terms. In addition, the Company shall pay Executive upon such termination or resignation, in exchange for the Executive complying with the obligations and restriction set forth or referred to in Section 8, the
severance payments and benefits due under Section eight (8)(a) above with respect to a Without Cause Termination, but such payments and benefits shall be provided for a period of twelve (12) months following termination or resignation
pursuant to this Section. 

  
 6 

 (b) A “Change in Control” shall be deemed to have occurred if
(i) a tender offer shall be made and consummated for the ownership of more than fifty percent (50%) of the outstanding voting securities of the Company, (ii) the Company shall be merged or consolidated with another corporation or
entity and as a result of such merger or consolidation less than fifty percent (50%) of the outstanding voting securities of the surviving or resulting corporation or entity shall be owned in the aggregate by the former shareholders of the
Company, as the same shall have existed immediately prior to such merger or consolidation, (iii) the Company shall sell all or substantially all of its assets to another corporation or entity which is not a wholly-owned subsidiary, or
(iv) a person, within the meaning of Section 3(a)(9) or of Section 13 (d)(3) (as in effect on the date hereof) of the Securities and Exchange Act of 1934 (“Exchange Act”), shall acquire more than fifty percent (50%) of
the outstanding voting securities of the Company (whether directly, indirectly, beneficially, or of record). For purposes hereof, ownership of voting securities shall take into account and shall include ownership as determined by applying the
provisions of Rule 13d-3(d)(1)(i) (as in effect on the date hereof) pursuant to the Exchange Act. 
 (c) A
resignation for “Good Reason” shall be deemed to have occurred if the Executive resigns his employment with the Company after the occurrence of any of the following events, to which the Executive has not expressly consented in writing:
(i) a material reduction in the Executive’s Base Salary (other than one applicable to all senior management); (ii) a material reduction in job duties, authority, responsibilities and requirements inconsistent with the Executive’s
position with the Company and the Executive’s prior duties, authority, responsibilities, and requirements or a change in the Executive’s reporting relationship; (iii) a relocation of the Executive to a facility or location more than
fifty (50) miles from the address of the Company’s headquarters office as of the effective date of this Agreement, or (iv) material breach by the Company of any of the material covenants herein. Any of the foregoing conditions
described in this Section 11(c) will constitute “Good Reason” only if the Executive first delivers a notice of termination to the Company identifying such condition (or conditions) within ninety (90) days after the initial
occurrence of such condition (or conditions) and such condition continues uncured for a period of thirty (30) days after the delivery of such notice of termination. Notwithstanding the foregoing, the Executive’s termination of employment
will not be considered to be for Good Reason unless the Company fails to cure such condition and such termination of employment occurs within sixty (60) days of the expiration of the Company’s (30) day cure period. 

(d) Notwithstanding anything to the contrary in Section 11, if payment of all severance payments and benefits under
Section 11(a) above (the “CIC Severance Benefits”) would, together with any other payments and benefits payable to or for the benefit of the Executive in connection with the Change in Control (together with the CIC Severance
Benefits,” the “CIC Benefits”), subject the Executive to tax under Code Section 4999, and if a reduction in the amount of the CIC Severance Benefits would result in the amount of the CIC Benefits, net of all federal and state
income taxes on the CIC Benefits (calculated at the highest marginal rates) and any taxes on the CIC Benefits 

  
 7 

 
under Code Section 4999 (such amount, the “Net After-Tax Receipts”), being equal to or greater than the Net After-Tax Receipts that would result from payment of the CIC Severance
Benefits without reduction, then the aggregate amount of the CIC Severance Benefits shall be reduced to the smallest amount that results in the Net After-Tax Receipts being equal to or greater than the Net After-Tax Receipts that would result if the
CIC Severance Benefits were reduced to any other amount. Any such reduction shall be implemented first by reducing the period during which the Executive continues to receive his Base Salary, then by reducing the amount of any other CIC Severance
Benefits payable in cash, and only thereafter by reducing the period during which other benefits and perquisites are provided. 
 Unless the Company and the Executive otherwise agree in writing, any determination required under this Section 11(d) will be made in writing by the Company’s independent public accountants or
such other person or entity to which the parties mutually agree (the “Firm”), whose determination will be conclusive and binding upon the Executive and the Company. For purposes of making the calculations required by this
Section 11(d), the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the
Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section. The Company will bear all costs the Firm may incur in connection with any calculations
contemplated by this Section 11(d). 
 12. Tax Provisions. 

(a) Notwithstanding any other provision of this Agreement whatsoever, the Company shall have the right, after consulting
with and securing the approval of the Executive (which approval shall not unreasonably be withheld), to provide for the application and effects of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (relating to
deferred compensation arrangements) and any related regulatory or administrative guidance issued by the Internal Revenue Service such that the severance and other benefits provided under this Agreement shall not trigger the additional tax, interest,
and any related penalties imposed by Code Section 409A(l)(B). Although the Company intends to administer the Agreement so that it will comply with the requirements of Code Section 409A, the Company does not represent or warrant that the
Agreement will comply with Code Section 409A or any other provision of federal, state, local or non-United States law. Neither the Company, its subsidiaries, nor their respective directors, officers, employees or advisers will be liable to the
Executive (or any other individual claiming a benefit through the Executive) for any tax, interest, or penalties the Executive may owe as a result of compensation paid under the Agreement, and the Company and its subsidiaries will have no obligation
to indemnify or otherwise protect the Executive from the obligation to pay any taxes pursuant to Code Section 409A. 

  
 8 

 (b) The Company shall delay the payment of any severance benefits payable
under this Agreement as required to comply with Code Section 409A(a)(2)(B)(i) (relating to payments made to certain “specified employees” of certain publicly-traded companies) and in such event, any such amount to which the Executive
would otherwise be entitled during the six (6) month period immediately following his termination of employment shall instead be accumulated through and paid or provided on the first business day following the expiration of such six
(6) month period, or if earlier, the date of his death. For the avoidance of doubt, no portion of any such severance benefits shall be subject to the foregoing delay if and to the extent that such benefits (i) constitute a “short term
deferral” within the meaning of Section 1.409A-1(a)(4) of the Treasury Regulations, or (ii) (A) are being paid due to the Executive’s “involuntary separation from service” (within the meaning of
Section 1.409A-1(n) of the Treasury Regulations); (B) do not exceed two times the lesser of (1) the Executive’s annualized compensation from the Company for the calendar year prior to the calendar year in which the termination
occurs, or (2) the maximum amount that may be taken into account under a qualified plan pursuant to Code Section 401(a)(17) for the year in which the Executive’s employment terminates; and (C) the payment is required under this
Agreement to be paid no later than the last day of the second (2nd) calendar year following the calendar year during which the Executive’s “separation from service” (within the meaning of Code Section 409A) occurs. For
purposes of Code Section 409A, the Executive’s right to receive installment payments pursuant to any provision in this Agreement shall be treated as a right to receive a series of separate and distinct payments. The determination of
whether the Executive is a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i) as of the time of his termination of employment shall made by the Company in accordance with the terms of Code Section 409A and the
applicable guidance thereunder (including without limitation Treasury Regulation Section 1.409A-1(i) and any successor provision thereto). 
 (c) The continued employee benefits available under Sections 8 and 11 above that are taxable benefits (and that are not disability pay or death benefit plans within the meaning of Code Section 409A)
are intended to comply, to the maximum extent possible, with the exception to Code Section 409A set forth in Section 1.409A-1(b)(9)(v) of the Treasury Regulations (and any successor thereto). To the extent that any of those benefits either
do not qualify for that exception, or are provided beyond the applicable time periods set forth in Section 1.409A-1(b)(9)(v) of the Treasury Regulations, then such amounts will be reimbursed or provided no later than December 31 of the
year following the year in which the expense was incurred and will be subject to the following additional rules: (i) the amount of in-kind benefits provided, during any calendar year shall not affect the amount of in-kind benefits to be
provided, during any other calendar year; and (ii) the right to in-kind benefits shall not be subject to liquidation or exchange for another benefit. 
 (d) For the avoidance of doubt, no amount subject to the requirements of Code Section 409A shall become payable to the Executive as a result of a termination of employment that does not constitute a
“separation from service” within the meaning of Code Section 409A(a)(2)(A)(i) and Section 1.409A-1(h) of the Treasury Regulations. 

  
 9 

 13. Consolidation; Merger or Sale of Assets. Nothing in this Agreement shall preclude
the Company from consolidating or merging into or with, or transferring all or substantially all of its assets to, another corporation that assumes this Agreement and all obligations and undertakings of the Company hereunder. Upon such a
consolidation, merger or sale of assets, the term “the Company” as used will mean the other corporation and this Agreement shall continue in full force and effect. 
 14. Modification. This Agreement may not be modified or amended except in writing signed by the parties. No term or condition of this Agreement will be deemed to have been waived, except in writing
by the party charged with waiver. A waiver shall operate only as to the specific term or condition waived and will not constitute a waiver for the future or act on anything other than that which is specifically waived. 

15. Governing Law. This Agreement has been executed and delivered in the State of Tennessee and its validity, interpretation,
performance and enforcement shall be governed by the laws of that state. 
 16. Notices. All notices, requests, consents
and other communications hereunder shall be in writing and shall be deemed to have been made when delivered or mailed first-class postage prepaid by registered mail, return receipt requested, or when delivered if by hand, overnight delivery service
or confirmed facsimile transmission, to the following: 
 (a) If to the Company, to: 

Chief Executive Officer 
 BioMimetic Therapeutics, Inc. 
 389 Nichol Mill Lane 

Franklin, TN 37067 
 with a copy to: 
 Legal Department 

BioMimetic Therapeutics, Inc. 
 389 Nichol Mill Lane 
 Franklin, TN 37067 

or at such other address as may have been furnished to the Executive by the Company in writing; or 

(b) If to the Executive, at: 5205 Shaw Ct., Brentwood, TN 37027, or such other address as may have been furnished to the
Company by the Executive in writing. 
 17. Entire Agreement. This Agreement, together with the Indemnification Agreement
and the previously executed Confidential Information and Inventions Agreement constitute the entire agreement between the Parties as to the subject matter hereof, and all prior negotiations, representations, agreements and understandings are merged
into, extinguished by and completely 

  
 10 

 
expressed by this Agreement. In the event of a conflict between this Agreement and the Confidential Information and Inventions Agreement, this Agreement shall supersede the Confidential
Information and Inventions Agreement. In the event of a conflict between this Agreement and the Indemnification Agreement, the Indemnification Agreement shall supersede this Agreement. 

18. Binding Agreement. This Agreement shall be binding on the parties’ successors, heirs and assigns. 

[Signature Page to Follow.] 

  
 11 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
the 17th day of July 2012. 

 

			
	LARRY BULLOCK
	
	 /s/ Larry Bullock

	
	BIOMIMETIC THERAPEUTICS, INC.
		
	By:	 	 /s/ Samuel E. Lynch

		 	Samuel E. Lynch
		 	President and Chief Executive Officer

  
 Signature Page
to Employment Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]